Oroxid

Phase 3Small molecule

CCharles University, Czech Republic

Oroxid is one of 27 small molecule programs targeting Oral. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OralRecruiting

OralPhase 3

Recruiting

Competition

Competitive Landscape

50 competitors in Oral

#DrugCompanyPhaseTrials

Vepesid

AAvyxa

Phase 2

1 2

Marinol

Jazz Pharmaceuticals

Phase 1

2 3

Oroxid

CCharles University, Czech Republic

Phase 3

1 4

GTX-104

GGrace Therapeutics Inc.

Phase 3

1 5

SHR-3167

JJiangsu HengRui Medicine Co., Ltd.

Phase 2

1 6

Nubain

AAultman Health Foundation

Preclinical

1 7

Pitressin

AAultman Health Foundation

Preclinical

1 8

DRSP/EE

Vertex Pharmaceuticals

Phase 1

1 9

VX-407

Vertex Pharmaceuticals

Phase 1

1 10

AB-101

AArtiva Biotherapeutics, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Oral1 trial

Oral Care With 3% Hydrogen Peroxide (Oroxid®) in ICU - Effects on the Lower Airway Microbial Colonisation

Recruiting·—·Phase 4·NCT06045429·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Oroxid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Oroxid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Oroxid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Charles University, Czech Republic company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCharles University, Czech Republic

Oroxid

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Oral1 trial

References

Drug Info

Quick Facts

Related News